Atrium Therapeutics

IPO

Paving a New Path for Precision Cardiology

Public · United States · Founded 2025 · $270.0M raised

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$270.0M
Last Round
$270.0M Venture RoundFeb 2026
Rounds
1
Type
Public

About

Atrium Therapeutics is a San Diego-based precision cardiology biotech that began trading on Nasdaq under ticker RNA on February 27, 2026, established as an independent spinoff in connection with Novartis AG's acquisition of Avidity Biosciences. The company develops RNA medicines for rare, life-threatening genetic cardiomyopathies, using a targeted delivery platform that couples the tissue selectivity of monoclonal antibodies and other ligands with siRNA payloads delivered directly to heart tissue. Its two lead development candidates are ATR-1072 for PRKAG2 syndrome and ATR-1086 for phospholamban (PLN) cardiomyopathy, alongside two undisclosed research-stage targets. Atrium launched with approximately $270 million in cash and cash equivalents and is led by President and CEO Kathleen Gallagher.

Summary

Atrium Therapeutics is a Biotech company based in United States, founded in 2025. It has raised $270.0M in total across 1 round, most recently a $270.0M Venture Round round in Feb 2026.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundFeb 2026
$270.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atrium Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/atrium-therapeutics"><img src="https://indexed.vc/api/badge/company/atrium-therapeutics" alt="Atrium Therapeutics on Indexed.vc" width="260" height="76" /></a>